Anti-SMN1 monoclonal antibody

Pre-made anti-SMN1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SMN1/SMN1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T71907-Ab-1/ GM-Tg-hg-T71907-Ab-2Anti-Human SMN1 monoclonal antibodyHuman
GM-Tg-rg-T71907-Ab-1/ GM-Tg-rg-T71907-Ab-2Anti-Rat SMN1 monoclonal antibodyRat
GM-Tg-mg-T71907-Ab-1/ GM-Tg-mg-T71907-Ab-2Anti-Mouse SMN1 monoclonal antibodyMouse
GM-Tg-cynog-T71907-Ab-1/ GM-Tg-cynog-T71907-Ab-2Anti-Cynomolgus/ Rhesus macaque SMN1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T71907-Ab-1/ GM-Tg-felg-T71907-Ab-2Anti-Feline SMN1 monoclonal antibodyFeline
GM-Tg-cang-T71907-Ab-1/ GM-Tg-cang-T71907-Ab-2Anti-Canine SMN1 monoclonal antibodyCanine
GM-Tg-bovg-T71907-Ab-1/ GM-Tg-bovg-T71907-Ab-2Anti-Bovine SMN1 monoclonal antibodyBovine
GM-Tg-equg-T71907-Ab-1/ GM-Tg-equg-T71907-Ab-2Anti-Equine SMN1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T71907-Ab-1/ GM-Tg-hg-T71907-Ab-2; GM-Tg-rg-T71907-Ab-1/ GM-Tg-rg-T71907-Ab-2;
GM-Tg-mg-T71907-Ab-1/ GM-Tg-mg-T71907-Ab-2; GM-Tg-cynog-T71907-Ab-1/ GM-Tg-cynog-T71907-Ab-2;
GM-Tg-felg-T71907-Ab-1/ GM-Tg-felg-T71907-Ab-2; GM-Tg-cang-T71907-Ab-1/ GM-Tg-cang-T71907-Ab-2;
GM-Tg-bovg-T71907-Ab-1/ GM-Tg-bovg-T71907-Ab-2; GM-Tg-equg-T71907-Ab-1/ GM-Tg-equg-T71907-Ab-2
Products NameAnti-SMN1 monoclonal antibody
Formatmab
Target NameSMN1
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SMN1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T71907-Ag-1Recombinant multi-species SMN/ SMN1/ BCD541 protein
    ORF Viral VectorvGMLP000812human SMN1 Lentivirus particle
    ORF Viral VectorpGMLP000812human SMN1 Lentivirus plasmid
    ORF Viral VectorpGMLPm001148mouse Smn1 Lentivirus plasmid
    ORF Viral VectorvGMLPm001148mouse Smn1 Lentivirus particle


    Target information

    Target IDGM-T71907
    Target NameSMN1
    Gene ID6606,677703
    Gene Symbol and SynonymsBCD541,GEMIN1,SMA,SMA1,SMA2,SMA3,SMA4,SMA@,SMN,SMN1,SMNT,T-BCD541,TDRD16A
    Uniprot AccessionQ16637
    Uniprot Entry NameSMN_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000172062
    Target ClassificationN/A

    The target: SMN1, gene name: SMN1, also named as BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3, SMA4, SMA@, SMN, SMNT, T-BCD541, TDRD16A. This gene is part of a 500 kb inverted duplication on chromosome 5q13. This duplicated region contains at least four genes and repetitive elements which make it prone to rearrangements and deletions. The repetitiveness and complexity of the sequence have also caused difficulty in determining the organization of this genomic region. The telomeric and centromeric copies of this gene are nearly identical and encode the same protein. However, mutations in this gene, the telomeric copy, are associated with spinal muscular atrophy; mutations in the centromeric copy do not lead to disease. The centromeric copy may be a modifier of disease caused by mutation in the telomeric copy. The critical sequence difference between the two genes is a single nucleotide in exon 7, which is thought to be an exon splice enhancer. Note that the nine exons of both the telomeric and centromeric copies are designated historically as exon 1, 2a, 2b, and 3-8. It is thought that gene conversion events may involve the two genes, leading to varying copy numbers of each gene. The protein encoded by this gene localizes to both the cytoplasm and the nucleus. Within the nucleus, the protein localizes to subnuclear bodies called gems which are found near coiled bodies containing high concentrations of small ribonucleoproteins (snRNPs). This protein forms heteromeric complexes with proteins such as SIP1 and GEMIN4, and also interacts with several proteins known to be involved in the biogenesis of snRNPs, such as hnRNP U protein and the small nucleolar RNA binding protein. Multiple transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.